Reuters Staff | MDedge

FDA pulls U.S. authorization for Eli Lilly’s COVID drug bebtelovimab

Publish date: December 5, 2022

The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.

Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development...

The AAP released six clinical reports and one policy statement covering a range of timely topics relevant to the health and care of children

NEW YORK - After a decade of follow-up in the Prostate Cancer Research International Active Surveillance (PRIAS) study, researchers have confirmed...

WASHINGTON - U.S.

NEW YORK (Reuters Health) - Helicobacter pylori treatment containing clarithromycin is associated with a short-term increase in the risk of...

NEW YORK (Reuters Health) - The risk of cataracts increases after percutaneous coronary intervention (PCI), suggesting the need for eye protection...

NEW YORK (Reuters Health) - About one in 20 bariatric surgery patients are readmitted to the hospital within 30 days of having the procedure,...

NEW YORK (Reuters Health) - Clinical practice in management of early-onset sepsis (EOS) in newborns varies widely across Europe, North America and...

NEW YORK - Intravascular ultrasound-guided (IVUS) stent implantation can lead to fewer adverse cardiac events compared with angiography-guided...

The U.S.